DEF: PetMed Express: 2026 Annual Meeting, Governance & Auditor

PetMed Express, Inc. announces its 2026 Annual Meeting of Shareholders to elect directors, approve executive compensation, and ratify a new independent auditor, Baker Tilly US, LLP, following the dismissal of RSM US LLP due to material weaknesses in internal controls.

Summary

• The 2025 Annual Meeting of Shareholders will be held virtually on January 21, 2026, at 11:00 a.m. Eastern Time.
• Shareholders will vote on the election of five director nominees, an advisory vote to approve named executive officer compensation, and the ratification of Baker Tilly US, LLP as the independent registered public accounting firm for the 2026 fiscal year.
• The Board of Directors recommends a vote 'FOR' all proposals.
• RSM US LLP was dismissed as the independent registered public accounting firm, and Baker Tilly US, LLP was appointed for the fiscal year ending March 31, 2026.
• Multiple material weaknesses in internal controls over financial reporting were identified, including issues with information technology general controls (ITGCs), errors in sales tax liability and Internal Revenue Code 162(m) application, and a material error in PetCareRx purchase accounting.
• An Audit Committee investigation (June-August 2025) revealed additional material weaknesses related to an ineffective control environment, risk assessment, information and communication process, and monitoring activities, including a failure to establish a proper 'tone at the top' and prompt reporting of whistleblower complaints.
• These issues led to restatements of consolidated financial statements for fiscal years ended March 31, 2023, 2022, and 2021, and unaudited condensed consolidated financial statements for various quarterly periods.
• The Board's size will be reduced from six to five persons following the Annual Meeting, due to Dr. Gian M. Fulgoni's retirement.
• Peter Batushansky and James LaCamp were appointed as new directors on April 9, 2025, and October 19, 2025, respectively.
• Leslie C.G. Campbell was appointed Interim Chief Executive Officer and President, and Executive Chair of the Board in August 2025, with Justin Mennen appointed Lead Independent Director.
• For fiscal year 2025, the Annual Incentive Plan (AIP) resulted in a 0% bonus payout for the CEO and CFO, as revenue ($226,972,000) and adjusted EBITDA ($672,000) significantly missed targets of $290,000,000 and $15,700,000, respectively.
• The CEO Pay Ratio for FY 2025 was 112:1, with the CEO's annualized total compensation at $3,949,232 and the median employee's total compensation at $35,319.

Sentiment

Score: 2

Explanation: The filing reveals severe underlying issues, including multiple material weaknesses in internal controls, significant financial misstatements requiring restatements across several fiscal years, and a complete failure to meet key financial performance targets (revenue and adjusted EBITDA) for FY 2025, resulting in zero executive bonuses. The dismissal of the previous auditor and the 'tone at the top' issues highlighted by an Audit Committee investigation indicate deep-seated governance and operational problems. While management changes and remediation efforts are underway, the extent and nature of these problems suggest a high degree of uncertainty and potential for continued poor performance. These factors collectively point to a company facing substantial challenges that could negatively impact future profitability and shareholder value.

Positives

• The company is committed to sound and effective corporate governance principles, with Corporate Governance Guidelines reviewed and updated annually.
• Active shareholder engagement and dialogue are integral to the company's corporate governance practices.
• The Board's composition reflects a balance of leadership, competencies, qualifications, and diversity of backgrounds and experience, with new directors bringing expertise in e-commerce, healthcare, technology, finance, and audit.
• The company demonstrates a strong commitment to animal welfare through adoption events, disaster relief efforts, and partnerships with organizations like the Florida Panthers and Golden State Warriors.
• A Veterinary Advisory Board (VAB) is in place to ensure initiatives improve patient care, advise on regulatory updates, and support educational content.
• An enterprise-wide information security program, including an Incident Response Policy and Procedure, is designed to assess, identify, and manage cybersecurity risks.
• A strong Executive Compensation Recovery Policy (Clawback Policy) is in place to recover incentive-based compensation in the event of accounting restatements or misconduct.
• Anti-Hedging and Anti-Pledging Policies prohibit directors, officers, and employees from engaging in speculative transactions or pledging company securities.

Negatives

• RSM US LLP was dismissed as the independent auditor due to identified material weaknesses in internal controls over financial reporting.
• Multiple material weaknesses in internal controls over financial reporting were identified for fiscal years ended March 31, 2025, 2024, and 2023.
• Financial statements for multiple periods required restatement due to errors in sales tax liability, Internal Revenue Code 162(m) application, PetCareRx purchase accounting, income tax provision calculation, and long-lived asset impairment evaluation.
• An Audit Committee investigation found an ineffective control environment, risk assessment process, information and communication process, and monitoring activities, including a lack of 'tone at the top' fostering ethical conduct.
• The former Audit Committee chair failed to promptly report whistleblower complaints to external auditors.
• The FY 2025 Annual Incentive Plan (AIP) resulted in a 0% bonus payout for the CEO and CFO, as financial performance goals (revenue and adjusted EBITDA) were not met.
• The CEO Pay Ratio for FY 2025 was 112:1, indicating a significant disparity between CEO and median employee compensation.

Risks

• Weaknesses in information technology general controls (ITGCs) in areas of user access, change management, and service organizations supporting financial reporting processes.
• Errors in the appropriate application of US GAAP relating to sales tax liability and misapplication of Internal Revenue Code 162(m).
• Material errors in PetCareRx purchase accounting related to the valuation of deferred tax assets and goodwill.
• Ineffective control environment, risk assessment process, information and communication process, and monitoring activities.
• Risks of financial misstatement due to error and/or fraud, including management override of controls.
• Lack of effective controls and procedures regarding the update of key accounting policies.
• Cybersecurity risks, which are overseen by the Audit Committee.
• Risks arising from compensation and human capital policies and programs.
• Risks associated with Board organization, membership, structure, succession planning for directors and executive officers, and corporate governance.
• Operating in a very competitive and rapidly changing environment, with new risks emerging over time.
• Forward-looking statements are based on estimates and assumptions that may turn out to be inaccurate, potentially causing actual results to differ materially.

Future Outlook

The company expects to benefit from the added commitment of employees due to their ownership or increased ownership of common stock through equity plans. It aims to continually pursue strategic opportunities while effectively managing the risks and challenges inherent to its business. The company intends to make strides to reduce its environmental impact while continuing to create positive economic and investor value over the long term.

Management Comments

• "We cordially invite you to attend the 2025 Annual Meeting of Shareholders... Your vote is important to us and to our business. We ask that you please cast your vote, as soon as possible." (Leslie C.G. Campbell)
• "Our Compensation and Human Capital Committee believes that this level of approval [92% approval of executive compensation in 2024] is indicative of our shareholders general support of our compensation philosophy and goals."
• "We believe pet health is deeply connected to the health and well-being of people beginning with pet families and extending to the veterinary community, animal shelters, animal welfare organizations, and those within our own business and supply chain."
• "We feel a strong sense of purpose in serving pet families and animal shelters, recognizing that our mission impacts a broad and diverse community. With this in mind, we see meaningful opportunities to make a positive difference in their lives."
• "We know that people are the key to our success. We are committed to hiring top talent, creating a company culture that includes a diversity of backgrounds, providing meaningful career development and competitive compensation, offering health and wellness programs for our employees and providing other resources, all of which enhance our workplace environment."
• "We believe that the work of sustainability starts with us and how we approach, assess, and monitor our business practices."

Industry Context

The company operates in the pet health, e-commerce, and specialty retail sectors. Its focus on animal welfare, adoption events, and a Veterinary Advisory Board aligns with growing trends in pet care and corporate social responsibility within the industry. The peer group used for compensation benchmarking, which includes companies like Medifast, CarParts.com, The Honest Company, and BARK, Inc., indicates a broad competitive landscape encompassing e-commerce and consumer goods beyond just pet supplies.

Comparison to Industry Standards

• The Compensation and Human Capital Committee consulted with Meridian Compensation Partners, LLC, a nationally recognized third-party compensation consulting firm, regarding compensation practices, industry trends, and executive/director pay.
• The peer group for FY 2025 compensation benchmarking included 16 companies (e.g., Medifast, Inc., Nature's Sunshine Products, Inc., GrowGeneration Corp., CarParts.com, Inc., The Honest Company, Inc., LifeVantage Corporation, The RealReal, Inc., ThredUp Inc., Mannatech, Incorporated, Purple Innovation, Inc., Weyco Group, Inc., Natural Alternatives International, Inc., Groupon, Inc., Rent the Runway, Inc., BARK, Inc., Grove Collaborative Holdings, Inc.).
• Peer group companies were selected based on a multi-factor screen aligning with the company's size, complexity, industry, and operational attributes, with revenue and market capitalization within a range of approximately 1/3x to 3x that of the company.
• The company's CEO pay ratio of 112:1 is provided for comparison to other public companies, as required by SEC rules.
• Performance stock units for Ms. Campos are tied to the company's total shareholder return relative to the S&P 600 Specialty Retail Index.
• The non-employee director compensation program was amended to modernize it and bring it into line with comparable peers, based on advice from Meridian Compensation Partners, LLC.

Management Changes

Corporate Governance

Related Party Transactions

• Since the beginning of the company's last fiscal year, the company has not had, or been a party to, nor is there currently proposed, a transaction with a related party.

Stakeholder Impact

• Shareholders: Directly impacted by the company's poor financial performance, internal control weaknesses, auditor change, and executive compensation decisions. Have an opportunity to vote on key governance matters.
• Employees: Compensation programs are designed to attract, reward, and retain top talent. The company employs 181 people, with approximately 59% racially or ethnically diverse and 65% female, and offers health and wellness programs.
• Customers: Benefit from the company's focus on pet health and welfare, including adoption events, disaster relief, and the guidance of a Veterinary Advisory Board aimed at improving patient care.
• Suppliers/Vendors: Protected by non-solicitation covenants for executives.
• Creditors: The company's financial performance and internal control issues could impact its creditworthiness and ability to meet obligations.

Next Steps

• Shareholders will vote on director elections, executive officer compensation, and auditor ratification at the Annual Meeting on January 21, 2026.
• The Board and the Compensation and Human Capital Committee will consider the outcome of the advisory vote on executive compensation when making future decisions.
• The company will continue to expend significant resources and take steps to remediate the identified material weaknesses in internal controls.
• The company will continue to make strides to reduce its environmental impact and develop a more comprehensive sustainability strategy.
• Final voting results from the Annual Meeting will be published in a Current Report on Form 8-K within 4 business days following the meeting.

Key Dates

Recommendation

The filing reveals severe underlying issues, including multiple material weaknesses in internal controls, significant financial misstatements requiring restatements across several fiscal years, and a complete failure to meet key financial performance targets (revenue and adjusted EBITDA) for FY 2025, resulting in zero executive bonuses. The dismissal of the previous auditor and the 'tone at the top' issues highlighted by an Audit Committee investigation indicate deep-seated governance and operational problems. While management changes and remediation efforts are underway, the extent and nature of these problems suggest a high degree of uncertainty and potential for continued poor performance. These factors collectively point to a company facing substantial challenges that could negatively impact future profitability and shareholder value, warranting a 'sell' recommendation.

Keywords

PetMed Express, proxy statement, corporate governance, executive compensation, auditor change, internal controls, material weaknesses, financial reporting, pet health, e-commerce, animal welfare, board of directors, shareholder meeting, DEF 14A